All Studies

Alkaloid fraction of Mirabilis jalapa Linn. flowers has low cytotoxicity and increases iron absorption through Erythropoietin-Matriptase-2-Hepcidin pathway in iron deficiency Hepatocarcinoma cell model.

Suselo YH et al (2023).
Saudi J Biol Sci.
PubMed:
36471797

Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery.

This article discusses the historical relevance of the approval of cannabidiol (CBD) for epilepsy treatment. Unlike its related compound, marijuana's Δ9-tetrahydrocannabinol, CBD does not have any euphorigenic or withdrawal effects at anticonvulsant doses. CBD also has anti-inflammatory properties. Though CBD's anticonvulsant properties were suggested in a few studies in rodent seizure models, social and regulatory pressures kept it from being clinically implemented. However, CBD was approved for the orphan disease Dravet syndrome in 2018 after its efficacy was established in randomized, placebo-controlled trials in children. The article suggests that CBD's approval is a key driver of a new discovery strategy for epilepsy treatment in the 21st century.

Del Pozo A and Barker-Haliski M (2023).
Exp Neurol.
PubMed:
36471511